Topotecin intravenous drip infusion (irinotecan hydrochloride hydrate) is indicated for treatment of pancreatic cancer.
Following discussions by the Review Committee for Unapproved or Off-label Use of Drugs with High Medical Needs, the Japanese regulatory body requested the company to develop Topotecin intravenous drip infusion.
Research-based pharmaceutical company Daiichi Sankyo is focused on promoting unapproved or off-label use of drugs with high medical needs to patients in need of them.